Whether you're sorting out the symptoms of an undiagnosed condition or grappling with the weight of a recent diagnosis, gastroparesis can be a complicated and daunting disease to navigate. You'll ...

The FDA requested additional studies be conducted to provide further evidence of efficacy. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals ...

WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug ...

Please provide your email address to receive an email when new articles are posted on . Tradipitant failed to meet statistically significant change in nausea severity at 12 weeks vs. placebo. Patients ...

Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the USPTO for a patent application covering the use of its GIMOTI® (metoclopramide) nasal spray in patients with moderate ...

Enrollment currently scheduled to begin in Q1 2026 M107 is the first potential disease-modifying drug for the treatment of gastroparesis M107’s mechanism of action has been shown to shift ...

Eating small frequent meals is among the dietary strategies that could improve gastric emptying. Recommendations include eating small frequent meals, chewing foods well, and limiting insoluble fiber.

- $40 million extension from existing investors Perceptive Advisors and CinRx Pharma brings the total Series B funding to $59 million - Extension to support continued development of deudomperidone ...

Gastroparesis is a digestive condition that can make life miserable for those who suffer from it. Ascension Sacred Heart Bay is the only hospital in the area that offers surgical treatment for the ...

$452.5 million in total milestone payments $2.5 million in near-term payments Double-digit royalties on future net product sales 3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 ...